Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8+ T cell control of tumor challenge in mice

Gabriel Dagotto, Alessandro Colarusso, Robert C Patio, David Li, Tochi Anioke, Victoria Giffin, Ruoran Guan, Trisha Anand, Esther Mbiwan, Malika Aid, Dan Barouch · 2024

Read Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8+ T cell control of tumor challenge in mice by Gabriel Dagotto, Alessandro Colarusso, Robert C Patio, David Li, Tochi Anioke, Victoria Giffin, Ruoran Guan, Trisha Anand, Esther Mbiwan, Malika Aid, Dan Barouch (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11660326.txt.

Description

Gabriel Dagotto and co-authors tested a viral cancer vaccine in mice in two thousand twenty-four. Cancer vaccines can target tumor-specific neoantigens. Peptide delivery is the common current route. Adenovirus vectors spark strong killer T cell responses. Their use for neoantigens was largely unexplored. The team built vaccines in a proven adenovirus strain.

Two mouse tumor models tested the vaccines. One was melanoma, the other colon cancer. Vector vaccines were compared with peptide ones. Protection was preventive: vaccine first, tumor challenge after. The best vector design expanded huge T cell pools. Those pools controlled tumor challenge better. Viral delivery may beat peptides for cancer vaccines. Human translation needs safety work first.

Catalog record

CREATORGabriel Dagotto, Alessandro Colarusso, Robert C Patio, David Li, Tochi Anioke, Victoria Giffin, Ruoran Guan, Trisha Anand, Esther Mbiwan, Malika Aid, Dan Barouch
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE54 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11660326

Browse the full library · About the Tower of Babel